MRK News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

MR

Mkt Cap

$372.32B

Volume

5.53K

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.The Motley Fool · Sep 22, 2026

Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?The article compares brokerage analyst recommendations (ABR) with Zacks Rank as investment decision tools. While Merck has a favorable average brokerage recommendation of 1.67 (Buy-equivalent), the article cautions that brokerage firms often exhibit positive bias due to vested interests. Zacks Rank, based on earnings estimate revisions rather than analyst opinions, is presented as a more reliable predictor of near-term stock price movements. Merck received a Zacks Rank #3 (Hold) due to unchanged earnings estimates, suggesting caution despite the bullish brokerage consensus.Zacks Investment Research · Sep 22, 2026

Should You Invest $1,000 in SCHD Right Now?The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22.8% year-to-date in 2026, outperforming the S&P 500's 11.8% gain. The rotation toward value and dividend stocks is expected to continue due to inflation concerns, higher interest rates, strong corporate earnings growth, and shrinking valuations. The ETF's focus on high-quality dividend-paying stocks positions it well for further gains.The Motley Fool · Sep 22, 2026

AZN vs. MRK: Comparing Keytruda, Pipelines and Growth StrategiesAstraZeneca and Merck are compared as investment opportunities in the pharmaceutical sector. AstraZeneca targets $80 billion in revenues by 2030 with 20 planned new medicine launches but faces patent expirations, pricing pressures in China, and recent pipeline setbacks. Merck relies heavily on blockbuster drug Keytruda (peak sales $35 billion by 2028) but faces patent expiration in 2028 and biosimilar competition. Merck receives a Zacks Rank #3 (Hold) while AstraZeneca receives Zacks Rank #5 (Strong Sell), making Merck the preferred choice despite higher valuation multiples.Zacks Investment Research · Sep 21, 2026

Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderBristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.The Motley Fool · Sep 20, 2026

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.Zacks Investment Research · Sep 15, 2026

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyImmunocore announced it has enrolled 540 patients in the phase III TEBE-AM study evaluating Kimmtrak as monotherapy and in combination with Merck's Keytruda versus investigator's choice in previously treated advanced melanoma. The company expects top-line overall survival data as early as end of 2026. Kimmtrak sales grew 16% year-over-year to $222.6 million in the first half of 2026.Zacks Investment Research · Sep 15, 2026

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth OpportunitiesThe global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.GlobeNewswire Inc. · Sep 15, 2026

Parexel to Lead Sessions at DPHARM 2026 on AI, Talent and the Future of Clinical OperationsParexel announced it will lead three expert panel sessions at DPHARM 2026 in Boston on enterprise AI adoption, workforce readiness, and patient-centric drug development. The company showcased its proprietary ParexelAI suite, which has delivered significant efficiency gains including 50% reduction in site selection timelines, 30% reduction in clinical study report preparation time, and 60% reduction in safety literature screening. CEO Peyton Howell and other executives will moderate discussions with leaders from major pharmaceutical companies including AbbVie, AstraZeneca, Boehringer Ingelheim, Regeneron, and Merck.GlobeNewswire Inc. · Sep 14, 2026

MR

MRKMerck & Co., Inc.

MRK

Pay with—

Available Balance0.00

Your PositionYou don't own any MRK yet.

Related Tickers

Earnings

Dividends

Last · Sep 15Quarterly

Amount$0.85

Yield2.25%

Annual$3.40